

Ablynx NV – “Nanobodies – Still Worth a Risk”

<https://marketpublishers.com/r/A59C652EBE9EN.html>

Date: November 2011

Pages: 4

Price: US\$ 140.00 (Single User License)

ID: A59C652EBE9EN

Abstracts

Pfizer’s returning of rights to the advanced anti-TNF (Ozoralizumab, ATN-103, PhIIb, RA) nanobody program to Ablynx (ABLX) has shaken investor’s confidence in the company. Outcome of the upcoming milestone (ALX-0081, PhII, anti-von Willebrand factor, Intravenous formulation data in ACS) is binary in nature. ABLX has established collaborations with major pharma companies for its technology platform. Ablynx is currently trading close to its cash value and could be a good target..... For more details, please read our report released on 9th November, 2011 on ABLX titled “Nanobodies – Still Worth a Risk!”

Contents

COMPANIES MENTIONED

Ablynx NV

I would like to order

Product name: Ablynx NV – “Nanobodies – Still Worth a Risk”

Product link: <https://marketpublishers.com/r/A59C652EBE9EN.html>

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A59C652EBE9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970